2452482
Cooperative Agreement
Overview
Grant Description
Ideas Lab: CFIRE: META-PURE: End-use-driven cell-free modules
-META-PURE: End-use-driven cell-free modules
Cell-free systems reduce biology to its most basic parts, simplifying the complexity of traditional biomanufacturing.
However, scientists still do not have an efficient way to “plug-and-play” these individual cell-free pieces.
This project addresses this gap by developing a modular, standardized platform for cell-free bioprocessing.
Instead of custom, one-off designs, the project creates eight reusable modules covering essential functions like energy generation and protein expression.
These “ready-to-use” modules make it easier to mix and match capabilities, allowing for faster, more efficient product development.
The team will demonstrate how modular design and standardized kits can reduce costs, improve accessibility, and boost productivity across three market-relevant targets.
In doing so, this project aims to make cell-free technologies broadly available and expand the use of cell-free technologies across the U.S. bioeconomy.
This project will also cultivate the next generation of biotechnology talent through a dynamic, cross-sector team of postdocs and graduate students—uniting expertise from industry, academia, and government—to pioneer and scale the future of cell-free biomanufacturing.
The project pioneers a modular, standardized framework to address bottlenecks for scaling cell-free bioprocessing.
The project will develop, characterize, and integrate eight distinct functional modules common across cell-free systems: three for energy generation, three for the synthesis of valuable products, and two for transcription-translation.
These modules span varying levels of complexity—from individual purified enzymes to enzyme cascades, purified recombinant elements (PURE), and lysate-based systems—encompassing the full spectrum of cell-free biotechnologies.
This modularity allows innovation beyond standalone PURE technologies; it comprises modules with defined capabilities, each built and optimized independently, then integrated to achieve more complex and ambitious synthesis goals.
The project also incorporates advanced analytical tools and establishes new standards and metrics to rigorously evaluate module performance and compatibility, which will result in a system that provides reliable synthesis.
Further, the system will be validated through the synthesis of three industrially relevant targets: the valuable small molecule santalene; the GAMS protein, which enhances cell-free protein expression; and production of a bacteriophage.
These demonstrations will show how the system can be used for a varied of use cases.
This project will accelerate innovation, enhance reproducibility, and demonstrate a replicable framework that enables flexible, cost-effective, and high-performance bio-based production platforms across diverse applications to support scalable biomanufacturing and strengthen the infrastructure of the U.S. bioeconomy.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are planned for this award.
-META-PURE: End-use-driven cell-free modules
Cell-free systems reduce biology to its most basic parts, simplifying the complexity of traditional biomanufacturing.
However, scientists still do not have an efficient way to “plug-and-play” these individual cell-free pieces.
This project addresses this gap by developing a modular, standardized platform for cell-free bioprocessing.
Instead of custom, one-off designs, the project creates eight reusable modules covering essential functions like energy generation and protein expression.
These “ready-to-use” modules make it easier to mix and match capabilities, allowing for faster, more efficient product development.
The team will demonstrate how modular design and standardized kits can reduce costs, improve accessibility, and boost productivity across three market-relevant targets.
In doing so, this project aims to make cell-free technologies broadly available and expand the use of cell-free technologies across the U.S. bioeconomy.
This project will also cultivate the next generation of biotechnology talent through a dynamic, cross-sector team of postdocs and graduate students—uniting expertise from industry, academia, and government—to pioneer and scale the future of cell-free biomanufacturing.
The project pioneers a modular, standardized framework to address bottlenecks for scaling cell-free bioprocessing.
The project will develop, characterize, and integrate eight distinct functional modules common across cell-free systems: three for energy generation, three for the synthesis of valuable products, and two for transcription-translation.
These modules span varying levels of complexity—from individual purified enzymes to enzyme cascades, purified recombinant elements (PURE), and lysate-based systems—encompassing the full spectrum of cell-free biotechnologies.
This modularity allows innovation beyond standalone PURE technologies; it comprises modules with defined capabilities, each built and optimized independently, then integrated to achieve more complex and ambitious synthesis goals.
The project also incorporates advanced analytical tools and establishes new standards and metrics to rigorously evaluate module performance and compatibility, which will result in a system that provides reliable synthesis.
Further, the system will be validated through the synthesis of three industrially relevant targets: the valuable small molecule santalene; the GAMS protein, which enhances cell-free protein expression; and production of a bacteriophage.
These demonstrations will show how the system can be used for a varied of use cases.
This project will accelerate innovation, enhance reproducibility, and demonstrate a replicable framework that enables flexible, cost-effective, and high-performance bio-based production platforms across diverse applications to support scalable biomanufacturing and strengthen the infrastructure of the U.S. bioeconomy.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.
Subawards are planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "IDEAS LAB: ADVANCING CELL-FREE SYSTEMS TOWARD INCREASED RANGE OF USE-INSPIRED APPLICATIONS", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF24552
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Atlanta,
Georgia
30332-0001
United States
Geographic Scope
Single Zip Code
Georgia Tech Research was awarded
Modular Cell-Free Bioprocessing Platform Scalable Bio-Based Production
Cooperative Agreement 2452482
worth $3,091,750
from National Science Foundation in July 2025 with work to be completed primarily in Atlanta Georgia United States.
The grant
has a duration of 3 years and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Cooperative Agreement was awarded through grant opportunity Ideas Lab: Advancing Cell-Free Systems Toward Increased Range of Use-Inspired Applications.
Status
(Ongoing)
Last Modified 7/10/25
Period of Performance
7/1/25
Start Date
6/30/28
End Date
Funding Split
$3.1M
Federal Obligation
$0.0
Non-Federal Obligation
$3.1M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2452482
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
491502 INNOVATION AND TECHNOLOGY ECOSYSTEMS
Funding Office
491501 TECHNOLOGY FRONTIERS
Awardee UEI
EMW9FC8J3HN4
Awardee CAGE
1G474
Performance District
GA-05
Senators
Jon Ossoff
Raphael Warnock
Raphael Warnock
Modified: 7/10/25